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was 9.4 months (1.5–21.5) and median overall survival was 
17.2 months (2.5–24.3). Only neutropenia (8%) was observed 
as an NCI-CTC grade 3 toxicity. Anemia and leucopenia 
grades 1 and 2 were the most common side effects.  Conclu-
sions: The combination of IGF shows a promising survival 
benefit with manageable toxicity in patients with advanced 
BTC. Therefore, this regimen seems to be a feasible second-
line treatment option for patients with rapid progression un-
der first-line therapy with gemcitabine and cisplatin and 
with a good performance status.  © 2016 S. Karger AG, Basel 
 Introduction 
 Cholangiocarcinoma are rare tumors with poor prog-
nosis  [1] . They originate intrahepatic or extrahepatic 
from the bile duct epithelium. Hilar carcinomas are 
known as Klatskin tumors. Gallbladder cancers are also 
associated with an unfavorable prognosis  [2] . Surgery is 
the only curative treatment option with 5-year survival 
rates of 0–40% after R0 resection  [3–5] . In advanced, 
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 Abstract 
 Background: Since 2010, combination therapy with gem-
citabine and cisplatin is the standard treatment for patients 
with biliary tract cancer (BTC) based on the ABC-02 trial. 
However, treatment after first-line progression is less clearly 
defined. We therefore retrospectively analyzed the efficacy 
of a 3-drug chemotherapy regimen in patients with ad-
vanced BTC.  Methods: Patients with advanced BTC treated 
with palliative chemotherapy between April 2000 and 
 October 2005 at Regensburg University Hospital were re-
viewed retrospectively. We analyzed the efficacy and safety 
of an institutional standard 3-drug regimen consisting of iri-
notecan, gemcitabine and 5-FU (IGF). One cycle, lasting 21 
days, included applications on days 1 and 8 consisting of 75 
mg/m 2 irinotecan i.v. for 90 min, 1,000 mg/m 2 gemcitabine 
i.v. for 30 min and 2,000 mg/m 2 fluorouracil (5-FU) for 24 h. 
 Results: A total of 12 histologically confirmed cases with 
gallbladder cancer and intrahepatic BTC were reviewed. Fif-
ty percent of the patients (6/12) had been pretreated with 
other chemotherapies. Median progression-free survival 
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nonresectable tumors, the median overall survival (OS) 
for these patients is 3–6 months  [1, 6, 7] .
 Palliative therapy options are limited. Systemic che-
motherapy with gemcitabine was the mainstay of treat-
ment in advanced biliary tract cancer (BTC) for a long 
time. Median survival was about 6 months in different 
phase II studies  [8] .
 In 2010, the first phase III randomized controlled mul-
ticenter trial (ABC-02) demonstrated a significant sur-
vival advantage for cisplatin plus gemcitabine compared 
with gemcitabine alone without an increase in toxicity 
 [9] . In this study, 410 patients with locally advanced or 
metastatic BTC were randomly assigned to receive either 
cisplatin plus gemcitabine or gemcitabine alone. The me-
dian OS was 11.7 months in the combination group and 
8.1 months in the gemcitabine group. Since this time, this 
combination therapy is the standard of care for the treat-
ment of patients with advanced BTC.
 A systematic review on gemcitabine and cisplatin for 
advanced BTC including one meta-analysis, 4 random-
ized controlled trials, 12 nonrandomized prospective 
studies and 3 retrospective studies supported the efficacy 
and safety of this combination  [10] . Median OS ranged 
from 4.6 to 11.7 months without substantial toxicity.
 Recently, a comprehensive analysis of 83 prospective 
trials in advanced BTC demonstrated that the combina-
tion of gemcitabine with platinum agents compared 
with other regimens shows a strong trend toward im-
proved response rate, but no significant difference in 
progression-free survival (PFS) or OS  [11] . Since the 
global effect of gemcitabine showed a strong statistical 
trend in OS and significant improvement in PFS while 
platinum containing regimens did not, this clinical ef-
fect seems mainly to be due to gemcitabine. Further-
more, in this study, gemcitabine-based combination 
therapies containing 5-FU showed a strong trend to-
ward an improved OS (9.5 vs. 12.5 months) relative to 
platinum agents. To date, a randomized phase III trial 
comparing gemcitabine and cisplatin vs. gemcitabine 
plus 5-FU is lacking.
 Treatment protocols after first-line progression are 
less clearly defined. Depending on the first-line setting, 
2-drug combinations of gemcitabine and 5-FU or platin 
and 5-FU plus oxaliplatin or irinotecan are commonly 
used  [12–14] . Irinotecan is a DNA topoisomerase I in-
hibitor, which has synergistic activity with 5-FU and 
gemcitabine  [15] . Therefore, we retrospectively evaluate 
the efficacy of a palliative 3-drug chemotherapy protocol 
consisting of irinotecan, gemcitabine and 5-FU (IGF) in 
patients with nonresectable BTC.
 Patients and Methods 
 Patients 
 We retrospectively analyzed individual chart reviews of 12 pa-
tients with histologically confirmed, nonresectable BTC, who were 
treated with a palliative chemotherapy consisting of IGF between 
April 2000 and October 2005 at the university clinic of Regens-
burg. Written consent was obtained in each case.
 IGF regimen consisted of 75 mg/m 2 irinotecan at a 90-min in-
fusion on days 1 and 8, followed by 1,000 mg/m 2 gemcitabine at a 
30-min infusion on days 1 and 8 and continuous infusion for 24 h 
of 2,000 mg/m 2 5-fluorouracil (days 1 and 8). This cycle was given 
every 21 days.
 Tumor response was evaluated with CT scans usually per-
formed every 2 cycles. Tumor response was evaluated and grad-
ed using WHO criteria  [16] . A complete response (CR) per site 
was defined as the complete disappearance of the disease. A par-
tial response (PR) was defined as a >50% decrease in the total 
lesion size without appearance of new lesions. Progressive dis-
ease (PD) was characterized either as a  ≥ 25% increase in lesion 
size or appearance of new lesions. Stable disease (SD) was de-
fined as a CR, PR or PD not demonstrated  ≥ 3 weeks after starting 
treatment.
 We excluded 2 patients from tumor response analysis: 1 patient 
received only one cycle of chemotherapy and was not available for 
response evaluation due to rapid progression. Another patient was 
not included because of a diagnosis of a second tumor (colorectal 
cancer) during chemotherapy.
 Statistical Analysis 
 Response rate, PFS, OS and safety were measured. Patients who 
received at least one infusion were assessable for safety. For hema-
tologic and biologic parameters, at least one measurement per cy-
cle was required. OS was defined as the time from the beginning 
of chemotherapy until death. PFS was defined as the time from the 
beginning of chemotherapy until disease progression or death, 
whichever occurred first. The duration of response was calculated 
as the time from the beginning of chemotherapy to progression.
 The Kaplan–Meier method was used to estimate OS and PFS 
outcomes. Statistical analysis was performed using the SPSS pro-
gram (version 12.0 for Windows).
 Results 
 Patient Characteristics 
 From April 2000 to October 2005, 12 patients were en-
rolled in the study. The baseline characteristics of the 12 
treated patients are listed in  table 1 . Fifty-eight percent 
female and 42% male patients were treated. The median 
age was 69 (range 49–73 years). Seventy-five percent 
(9/12) of patients had intrahepatic cholangiocarcinoma; 
25% (3/12) had gallbladder cancer.
 Six of 12 patients (50%) were pretreated with different 
chemotherapy protocols with pioglitazone, rofecoxib, 
capecitabine, gemcitabine and oxaliplatin ( table 1 ).
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
25
 - 
2/
13
/2
01
7 
3:
09
:5
1 
PM
 Irinotecan, Gemcitabine and Fluorouracil 
in Biliary Cancer 
Digestion 2016;93:229–233
DOI: 10.1159/000445187
231
 Treatment Administration 
 A total of 80 cycles were completed (median 5 cycles 
per patient; range 1–16 cycles). All patients received at 
least one dose of chemotherapy and were eligible for safe-
ty analysis. The median dose-intensity was 99% for irino-
tecan (50.7–101.8%), 100% for gemcitabine (50.0–
100.0%) and 100% for 5-FU (49.5–100.5%).
 Toxicity 
 Twelve patients could be assessed for safety. No treat-
ment-related deaths occurred. NCI-CTC grades 3 and 4 
toxicity were rare. Severe hematologic toxicities were ob-
served only with respect to neutropenia (grade 3: 8%). 
Anemia grades 1 and 2 were regarded as a common side 
effect of the chemotherapy (8/12, 67% and 3/12, 25%, re-
spectively). Despite antiemetic medication, nausea affect-
ed most of the patients. Sixty-seven percent (8/12) of pa-
tients suffered from nausea. Grade 1 vomiting was ob-
served in 33% (4/12) of patients and grade 2 in 17% (2/12) 
of patients. Three patients (25%) experienced diarrhea 
grades 1 and 2 and only 1 patient (8%) had grade 3.
 Objective Response and Survival 
 Ten patients could be assessed for response analysis 
( table 2 ;  fig. 1 ). No objective treatment responses or re-
gression of tumors were observed. Seven patients (70%) 
had SD. For survival analysis all 12 patients were includ-
ed: median PFS was 9.4 months (1.5–21.5); median OS 
was 17.2 months (2.5–24.3).
 Discussion 
 BTC is a rare and aggressive tumor. The treatment of 
metastatic BTC still remains a challenge. In our retro-
spective analysis of patients with advanced BTC, we eval-
uated the efficacy and safety of a 3-drug regimen consist-
ing of IGF. While the response rate was 0, 70% of patients 
had SD with a promising median PFS of 9.4 months and 
a median OS of 17.2 months. There were no grade 4 tox-
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 Fig. 1. Kaplan–Meier estimates of OS. 
Table 1.  Characteristics of treated patients
Number of patients n = 12 %
Gender
Male 5 41.7
Female 7 58.3
Age, years
Median 69 –
Range 49–73 –
Localization of the primary tumor
Intrahepatic cancer 9 75
Gallbladder cancer 3 25
Prior treatment
None 5 41.7
Operative resection 1 8.3
Chemotherapy* 6 50
 * Different chemotherapy protocols with pioglitazone, rofe-
coxib, capecitabine, gemcitabine and oxaliplatin.
Table 2.  Efficacy results
Anzahl %
Tumor response after 6 cycles (n = 10)
CR 0 0
PR 0 0
SD 7 70
PD 3 30
Time to tumor progression (n = 12), months
Median 9.436
Range 1.51–21.53
OS (n = 12), months  
Median 17.24
Range 2.50–24.32
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icities, and grade 3 side effects such as leucopenia were 
found only in 1 patient (8%).
 There are few published reports about the treatment of 
advanced BTC with 3-drug combinations and to our 
knowledge determined only in first-line treatment so far: 
Petrioli et al.  [17] could show that 3-weekly oxaliplatin 
combined with gemcitabine and oral capecitabine in the 
first-line treatment of 37 patients with advanced BTC is 
an active and well-tolerated chemotherapy regimen. The 
overall response rate was 35% and the disease control rate 
was 73%. The median PFS was 9.4 months (95% CI 4.1–
12.2 months) and the median OS was 13.8 months (95% 
CI 7.7–17.1 months). Analogous to our study, there were 
no grade 4 toxicities and grade 3 neutropenia in 13.5% of 
patients and grade 3 thrombocytopenia in 10.8%.
 In a multi-institution phase II study, Kanai et al.  [18] 
evaluated the efficacy and safety of gemcitabine/cisplatin/ 
S-1 combination chemotherapy in 50 patients with ad-
vanced BTC. Comparable to our data, the median OS was 
promising with 16.2 months. Toxicity was manageable with 
grades 3–4 neutropenia in 32%, anemia in 32% and throm-
bocytopenia in 10%. Febrile neutropenia occurred in 4%.
 In 2010, Yamashita et al.  [19] also reported a signifi-
cant antitumor activity of gemcitabine/5-FU/cisplatin in 
21 patients with advanced BTC: median OS was 18.8 
months and PFS was 13.4 months. Hematological grade 
3 toxicity, such as leucopenia, thrombocytopenia and 
anemia, was found in 6 patients (28.6%).
 A further small study on 14 patients with advanced 
BTC could demonstrate an overall response rate of 21.4% 
with a triple combination chemotherapy consisting of 
gemcitabine, 5-FU and cisplatin  [20] . SD was observed in 
64.3% and clinical benefit in even 85.7%.
 On the other hand, Wagner et al.  [21] achieved com-
parable results for response and survival to previously re-
ported regimens (median OS 10 months) with the com-
bination of gemcitabine, oxaliplatin and 5-FU in patients 
with advanced BTC and gallbladder cancer, but with 
more toxicity.
 However, according to others (17–20), a 3-drug 
combination chemotherapy was a safe and feasible 
treatment option in the second-line setting, which re-
sulted in a clinically relevant stabilization rate in the 
pretreated patients with advanced BTC. Consequently, 
IGF might be a helpful treatment option for patients 
with BTC and a good performance status after rapid 
progression under first-line therapy with gemcitabine 
and cisplatin. 
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